Trials / Completed
CompletedNCT02960854
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2016-12-07
- Primary completion
- 2018-01-05
- Completion
- 2018-01-05
- First posted
- 2016-11-10
- Last updated
- 2019-04-23
- Results posted
- 2019-04-04
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02960854. Inclusion in this directory is not an endorsement.